Get started
Author

Gavin S. Choy

Adefovir Dipivoxil Therapy for Lamivudine–Resistant Hepatitis B in Pre- and Post-Liver Transplantation Patients
2003 · Eugene R. Schiff, Ching-Lung Lai, et al. · Hepatology · 371
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
2014 · Fang Fang, Joanne Munck, et al. · Clinical Cancer Research · 97
SGI-110. DNA methyltransferase inhibitor, Oncolytic
2013 · Griffiths, E.A., Choy, G., et al. · Drugs of the Future · 76
The Benefits of In‐Home Pharmacy Evaluation for Older Persons
1997 · Elaine Hsia Der, Laurence Z. Rubenstein, et al. · Journal of the American Geriatrics Society · 50
First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)
2013 · Hagop M. Kantarjian, Elias Jabbour, et al. · Blood · 33
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors
2014 · Monica Mita, Michael Gordon, et al. · Cancer Chemotherapy and Pharmacology · 28
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
2011 · D Mahalingam, C M Espitia, et al. · British Journal of Cancer · 27
PDF
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
2012 · Raoul Tibes, Gil Fine, et al. · Cancer Chemotherapy and Pharmacology · 26
424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)
2004 · T.T. Chang, M. Shiffman, et al. · Journal of Hepatology · 23
Targeting PIM kinase activity significantly augments the efficacy of cytarabine
2011 · Kevin R. Kelly, Claudia M. Espitia, et al. · British Journal of Haematology · 22
PDF
Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML
2012 · Hagop M. Kantarjian, Gail J. Roboz, et al. · Blood · 20
45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients
2004 · M. Shiffman, P. Marcellin, et al. · Journal of Hepatology · 17
Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models
2018 · Zhao Wei, Ling Yang, et al. · Molecular Cancer Therapeutics · 12
Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models
2017 · Joe Shih, Boyu Zhong, et al. · Cancer Research · 12
A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.
2006 · Francis Giles, David A. Rizzieri, et al. · Blood · 11
171 Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts
2010 · P. Taverna, L. Huang, et al. · European Journal of Cancer Supplements · 9
Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML
2012 · Jean Pierre Issa, Gail Roboz, et al. · Cancer Research · 7
First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).
2014 · Elizabeth A. Griffiths, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 6
Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST).
2013 · Daruka Mahadevan, Geoffrey Shapiro, et al. · Journal of Clinical Oncology · 6
Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers
2012 · Gavin Choy, Rajashree Joshi-Hangal, et al. · Cancer Chemotherapy and Pharmacology · 6
Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).
2013 · Lauren Byers, Leora Horn, et al. · Cancer Research · 5
SGI-110. DNA methyltransferase inhibitor, Oncolytic
2013 · E.A. Griffiths, G. Choy, et al. · Drugs of the Future · 5
Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates
2010 · P. A. Baxter, P. A. Thompson, et al. · Cancer Chemotherapy and Pharmacology · 5
Vinorelbine liposomes injection results in greater tumor drug exposure compared to conventional vinorelbine in tumor-bearing nude mice
2007 · Steven R. Deitcher, Pieter R. Cullis, et al. · Molecular Cancer Therapeutics · 5
Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)
2014 · Gini Fleming, Sharad Ghamande, et al. · Cancer Research · 4
Works count: 73
Citation count: 922
H-index: 12
I10-index: 15
Year
Topic
Type